No October surprise here. AbbVie’s Humira is once again the top-spending TV pharma advertiser for the month. However, maybe just a little surprising is that its spending of $39.1 million was up 85% year-over-year from last October’s $21.1 million in spending.
Pfizer’s second-quarter results got a big boost from its Hospira buyout: The biosims-and-generics-focused acquisition helped drive an 11% revenue increase to $13.15 billion, beating analyst expectations.
Pharma's top TV spenders for April featured blockbusters and cliffhangers. The top three--Pfizer's Lyrica, AbbVie's Humira and Sunovion's Latuda--have brought home lots of bacon, but now they're facing their own patent expirations.